The company said total revenue for the quarter was $31.2 million -- a 215% increase over the same period in 2020, when it reported $9.9 million. The company's net income was $7.9 million compared with a net loss of $16.4 million in the corresponding quarter of 2020.

Total revenue for the six months of fiscal 2021 year to date was $48.1 million, a 118% increase from $22.1 million for the same period of 2020. The firm's net income year to date was $6.8 million compared with a net income of $5.9 million for first six months of 2020.

The company cited a few operating-related highlights for the quarter, including the acquisition of Stirling Ultracold, which became a wholly owned subsidiary on May 3, and that it processed 14 new U.S. Food and Drug Administration drug master file cross-reference requests.

BioLife Solutions to acquire Sexton Biotechnologies
BioLife Solutions, a supplier of cell and gene therapy bioproduction tools, plans to acquire Sexton Biotechnologies for $24 million.

BioLife Solutions launches freezer for cell and gene therapy developers
BioLife Solutions has launched a new line of high-capacity, controlled-rate freezers with a focus on the cell and gene therapy industry.

BioLife Solutions invests in cell and gene therapy products
BioLife Solutions, a supplier of cell and gene therapy bioproduction tools, along with innovation accelerator partner Casdin Capital, have invested in...